MedTrace Logo

Phase I Study of HC-7366 for Acute Myeloid Leukemia

NCT06285890 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2026-05-15

No results posted yet for this study

Summary

To find a recommended dose of HC-7366 to patients with AML. The safety and effects of this drug combination will also be studied.

Conditions

Interventions

DRUG

HC-7366

Given by PO

Sponsors & Collaborators

  • HiberCell, Inc.

    collaborator INDUSTRY

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Abhishek Maiti, MD · M.D. Anderson Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-20
Primary Completion
2027-12-31
Completion
2029-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06285890 on ClinicalTrials.gov